Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.

Flora DR, Rettie AE, Brundage RC, Tracy TS.

J Clin Pharmacol. 2017 Mar;57(3):382-393. doi: 10.1002/jcph.813. Epub 2016 Sep 22.

PMID:
27539372
2.

Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism.

Bostick CD, Hickey KM, Wollenberg LA, Flora DR, Tracy TS, Gannett PM.

Drug Metab Dispos. 2016 May;44(5):741-9. doi: 10.1124/dmd.115.067637. Epub 2016 Mar 9.

3.

Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Tracy TS, Chaudhry AS, Prasad B, Thummel KE, Schuetz EG, Zhong XB, Tien YC, Jeong H, Pan X, Shireman LM, Tay-Sontheimer J, Lin YS.

Drug Metab Dispos. 2016 Mar;44(3):343-51. doi: 10.1124/dmd.115.067900. Epub 2015 Dec 17. Review.

4.

Nanoscale electron transport measurements of immobilized cytochrome P450 proteins.

Bostick CD, Flora DR, Gannett PM, Tracy TS, Lederman D.

Nanotechnology. 2015 Apr 17;26(15):155102. doi: 10.1088/0957-4484/26/15/155102. Epub 2015 Mar 25.

5.

A coming disruption in pharmacy?

Romanelli F, Tracy TS.

Am J Pharm Educ. 2015 Feb 17;79(1):01. doi: 10.5688/ajpe79101. No abstract available.

6.

Social network analysis to assess the impact of the CTSA on biomedical research grant collaboration.

Nagarajan R, Peterson CA, Lowe JS, Wyatt SW, Tracy TS, Kern PA.

Clin Transl Sci. 2015 Apr;8(2):150-4. doi: 10.1111/cts.12247. Epub 2014 Nov 30.

7.

Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions.

Ramsden D, Tweedie DJ, Chan TS, Tracy TS.

Drug Metab Dispos. 2014 Nov;42(11):1940-6. doi: 10.1124/dmd.114.057901. Epub 2014 Aug 25.

8.

Comparison of U.S. and Chinese pharmacy education programs.

Yi ZM, Zhao RS, Zhai SD, Yang L, Hu YF, Yang YH, Zhang X, Tracy TS.

Am J Health Syst Pharm. 2014 Mar 1;71(5):425-9. doi: 10.2146/ajhp130611. No abstract available.

PMID:
24534598
9.

microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450.

Lamba V, Ghodke Y, Guan W, Tracy TS.

Biochem Biophys Res Commun. 2014 Mar 7;445(2):404-11. doi: 10.1016/j.bbrc.2014.02.024. Epub 2014 Feb 12.

10.

Case study 3. Application of basic enzyme kinetics to metabolism studies: real-life examples.

Li Y, McCabe M, Podila L, Tracy TS, Tweedie DJ.

Methods Mol Biol. 2014;1113:441-60. doi: 10.1007/978-1-62703-758-7_20.

PMID:
24523124
11.

Different enzyme kinetic models.

Seibert E, Tracy TS.

Methods Mol Biol. 2014;1113:23-35. doi: 10.1007/978-1-62703-758-7_3. Review.

PMID:
24523107
12.

Fundamentals of enzyme kinetics.

Seibert E, Tracy TS.

Methods Mol Biol. 2014;1113:9-22. doi: 10.1007/978-1-62703-758-7_2. Review.

PMID:
24523106
13.

The use of immobilized cytochrome P4502C9 in PMMA-based plug flow bioreactors for the production of drug metabolites.

Wollenberg LA, Kabulski JL, Powell MJ, Chen J, Flora DR, Tracy TS, Gannett PM.

Appl Biochem Biotechnol. 2014 Feb;172(3):1293-306. doi: 10.1007/s12010-013-0537-z. Epub 2013 Oct 30.

14.

Measurement of electron transfer through cytochrome P450 protein on nanopillars and the effect of bound substrates.

Jett JE, Lederman D, Wollenberg LA, Li D, Flora DR, Bostick CD, Tracy TS, Gannett PM.

J Am Chem Soc. 2013 Mar 13;135(10):3834-40. doi: 10.1021/ja309104g. Epub 2013 Mar 4.

15.

Selective filling of nanowells in nanowell arrays fabricated using polystyrene nanosphere lithography with cytochrome P450 enzymes.

Wollenberg LA, Jett JE, Wu Y, Flora DR, Wu N, Tracy TS, Gannett PM.

Nanotechnology. 2012 Sep 28;23(38):385101. doi: 10.1088/0957-4484/23/38/385101. Epub 2012 Sep 4.

16.

Localized delivery of chemotherapy to the cervix for radiosensitization.

Hodge LS, Downs LS Jr, Chura JC, Thomas SG, Callery PS, Soisson AP, Kramer P, Wolfe SS, Tracy TS.

Gynecol Oncol. 2012 Oct;127(1):121-5. doi: 10.1016/j.ygyno.2012.07.097. Epub 2012 Jul 14.

PMID:
22796462
17.

Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.

Subramanian M, Agrawal V, Sandee D, Tam HK, Miller WL, Tracy TS.

Pharmacogenet Genomics. 2012 Aug;22(8):590-7. doi: 10.1097/FPC.0b013e3283544062.

PMID:
22547083
18.

Development of an in vitro system with human liver microsomes for phenotyping of CYP2C9 genetic polymorphisms with a mechanism-based inactivator.

Flora DR, Tracy TS.

Drug Metab Dispos. 2012 Apr;40(4):836-42. doi: 10.1124/dmd.111.043372. Epub 2011 Dec 28.

19.
20.

Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells.

Hodge LS, Taub ME, Tracy TS.

Biochem Pharmacol. 2011 Apr 1;81(7):950-6. doi: 10.1016/j.bcp.2011.01.016. Epub 2011 Feb 1.

PMID:
21291869
21.

Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors.

Zhou J, Tracy TS, Remmel RP.

Drug Metab Dispos. 2011 Feb;39(2):322-9. doi: 10.1124/dmd.110.035030. Epub 2010 Oct 28.

22.

Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.

Sandee D, Morrissey K, Agrawal V, Tam HK, Kramer MA, Tracy TS, Giacomini KM, Miller WL.

Pharmacogenet Genomics. 2010 Nov;20(11):677-86. doi: 10.1097/FPC.0b013e32833f4f9b.

23.

Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1.

Zhou J, Tracy TS, Remmel RP.

Drug Metab Dispos. 2010 Nov;38(11):1907-11. doi: 10.1124/dmd.110.033829. Epub 2010 Jul 28.

24.

CYP2C9-CYP3A4 protein-protein interactions: role of the hydrophobic N terminus.

Subramanian M, Tam H, Zheng H, Tracy TS.

Drug Metab Dispos. 2010 Jun;38(6):1003-9. doi: 10.1124/dmd.109.030155. Epub 2010 Mar 9.

25.
26.

CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.

Subramanian M, Low M, Locuson CW, Tracy TS.

Drug Metab Dispos. 2009 Aug;37(8):1682-9. doi: 10.1124/dmd.109.026500. Epub 2009 May 15.

27.

Electrocatalytic drug metabolism by CYP2C9 bonded to a self-assembled monolayer-modified electrode.

Yang M, Kabulski JL, Wollenberg L, Chen X, Subramanian M, Tracy TS, Lederman D, Gannett PM, Wu N.

Drug Metab Dispos. 2009 Apr;37(4):892-9. doi: 10.1124/dmd.108.025452. Epub 2009 Jan 26.

28.

Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.

Mosher CM, Hummel MA, Tracy TS, Rettie AE.

Biochemistry. 2008 Nov 11;47(45):11725-34. doi: 10.1021/bi801231m. Epub 2008 Oct 16.

29.

Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection.

Hutzler JM, Balogh LM, Zientek M, Kumar V, Tracy TS.

Drug Metab Dispos. 2009 Jan;37(1):59-65. doi: 10.1124/dmd.108.023358. Epub 2008 Oct 6.

30.

Your role and responsibilities in the manuscript peer review process.

Brazeau GA, Dipiro JT, Fincham JE, Boucher BA, Tracy TS.

Am J Pharm Educ. 2008 Jun 15;72(3):69. No abstract available.

31.

Pharm. D. pathways to biomedical research: the National Institutes of Health special conference on pharmacy research.

Figg WD, Chau CH, Okita R, Preusch P, Tracy TS, McLeod H, Reed M, Pieper J, Knoell D, Miller K, Speedie M, Blouin R, Kroboth P, Koda-Kimble MA, Taylor P, Cohen J, Giacomini K.

Pharmacotherapy. 2008 Jul;28(7):821-33. doi: 10.1592/phco.28.7.821.

PMID:
18576897
32.

Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone.

Hummel MA, Gannett PM, Aguilar J, Tracy TS.

Arch Biochem Biophys. 2008 Jul 15;475(2):175-83. doi: 10.1016/j.abb.2008.04.034. Epub 2008 May 1.

33.

Studying cytochrome P450 kinetics in drug metabolism.

Kramer MA, Tracy TS.

Expert Opin Drug Metab Toxicol. 2008 May;4(5):591-603. doi: 10.1517/17425255.4.5.591 . Review.

PMID:
18484917
34.

Differential genotype dependent inhibition of CYP2C9 in humans.

Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS.

Drug Metab Dispos. 2008 Jul;36(7):1242-8. doi: 10.1124/dmd.108.020396. Epub 2008 Mar 31.

35.

Alterations in drug disposition during pregnancy: implications for drug therapy.

Hodge LS, Tracy TS.

Expert Opin Drug Metab Toxicol. 2007 Aug;3(4):557-71. Review.

PMID:
17696806
36.

Polymorphic variants of CYP2C9: mechanisms involved in reduced catalytic activity.

Wei L, Locuson CW, Tracy TS.

Mol Pharmacol. 2007 Nov;72(5):1280-8. Epub 2007 Aug 8.

37.
38.

CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.

Locuson CW, Wienkers LC, Jones JP, Tracy TS.

Drug Metab Dispos. 2007 Jul;35(7):1174-81. Epub 2007 Apr 19.

39.

Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.

Locuson CW, Gannett PM, Ayscue R, Tracy TS.

J Med Chem. 2007 Mar 22;50(6):1158-65. Epub 2007 Feb 21.

40.

Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common.

Locuson CW, Hutzler JM, Tracy TS.

Drug Metab Dispos. 2007 Apr;35(4):614-22. Epub 2007 Jan 24.

41.

Atypical cytochrome p450 kinetics: implications for drug discovery.

Tracy TS.

Drugs R D. 2006;7(6):349-63. Review.

PMID:
17073518
42.

Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.

Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA.

Br J Clin Pharmacol. 2007 Apr;63(4):477-87. Epub 2006 Oct 19.

43.

CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles.

Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS.

Drug Metab Dispos. 2006 Dec;34(12):1966-75. Epub 2006 Sep 8.

44.

Identification of binding sites of non-I-helix water molecules in mammalian cytochromes p450.

Locuson CW, Tracy TS.

Drug Metab Dispos. 2006 Dec;34(12):1954-7. Epub 2006 Sep 6.

45.

Validation of incorporating flurbiprofen into the Pittsburgh cocktail.

Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA.

Clin Pharmacol Ther. 2006 Sep;80(3):257-63.

PMID:
16952492
46.

Enzyme source effects on CYP2C9 kinetics and inhibition.

Kumar V, Rock DA, Warren CJ, Tracy TS, Wahlstrom JL.

Drug Metab Dispos. 2006 Nov;34(11):1903-8. Epub 2006 Aug 23.

47.

Amiodarone analog-dependent effects on CYP2C9-mediated metabolism and kinetic profiles.

Kumar V, Locuson CW, Sham YY, Tracy TS.

Drug Metab Dispos. 2006 Oct;34(10):1688-96. Epub 2006 Jun 30.

48.

Preparation, characterization, and substrate metabolism of gold-immobilized cytochrome P450 2C9.

Gannett PM, Kabulski J, Perez FA, Liu Z, Lederman D, Locuson CW, Ayscue RR, Thomsen NM, Tracy TS.

J Am Chem Soc. 2006 Jul 5;128(26):8374-5.

49.

Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9.

Locuson CW, Gannett PM, Tracy TS.

Arch Biochem Biophys. 2006 May 15;449(1-2):115-29. Epub 2006 Mar 2.

PMID:
16545770
50.

Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9.

Hummel MA, Tracy TS, Hutzler JM, Wahlstrom JL, Zhou Y, Rock DA.

J Biomol Screen. 2006 Apr;11(3):303-9. Epub 2006 Feb 20.

PMID:
16490777

Supplemental Content

Loading ...
Support Center